Venture Life Delivers Double-Digit Growth as It Doubles Down on Branded Consumer Healthcare

Venture Life ( (GB:VLG) ) has shared an announcement.

Venture Life Group reported a strong twelve-month trading performance to 31 December 2025, with revenue from continuing operations rising 32% to £35.1 million, or 11.1% on a proforma basis, driven predominantly by volume growth and robust expansion of its Power Brands portfolio. UK revenues surged 20.7% to £25.7 million following increased advertising and promotion, with standout gains from Balance Activ, Earol, and a 44% proforma jump in the Health & Her/Him brands, while international revenues fell 8.7% due mainly to order timing and temporary distributor disruption that has now been resolved. The group has completed its pivot to a pure branded consumer healthcare model after disposing of its CDMO operations, is consolidating international management into its UK commercial team to build larger, more strategic partnerships, and is investing heavily in new product development in collaboration with Healthea Group alongside a new Microsoft Dynamics 365 ERP system to support a data- and digital-led strategy. Backed by a strong net cash position of £34.4 million, an ongoing share buyback programme, and an active pipeline of earnings-enhancing M&A targets in women’s and men’s health, energy management and hormonal health, the board reiterated confidence in meeting revenue and adjusted EBITDA expectations for the extended 17-month period to 31 May 2026.

The most recent analyst rating on (GB:VLG) stock is a Hold with a £65.00 price target. To see the full list of analyst forecasts on Venture Life stock, see the GB:VLG Stock Forecast page.

Spark’s Take on GB:VLG Stock

According to Spark, TipRanks’ AI Analyst, GB:VLG is a Neutral.

Venture Life’s stock score is primarily supported by strong technical indicators and positive corporate events, such as share buybacks and insider buying, which suggest confidence in future prospects. However, the high P/E ratio and profitability challenges weigh down the score, indicating potential overvaluation and financial risks.

To see Spark’s full report on GB:VLG stock, click here.

More about Venture Life

Venture Life Group is a UK-headquartered international consumer self-care company focused on developing and commercialising over-the-counter healthcare products for the global self-care market. Its portfolio includes women’s intimate healthcare brand Balance Activ, ENT care spray Earol, Lift and Glucogel for energy and glucose management and hypoglycaemia, and the Health & Her range supporting the hormonal lifecycle, sold through pharmacies, health and beauty retailers, grocery chains and e-commerce channels, both directly in core markets and via international distribution partners elsewhere.

Average Trading Volume: 227,042

Technical Sentiment Signal: Buy

Current Market Cap: £82.42M

See more data about VLG stock on TipRanks’ Stock Analysis page.